Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 11 | 2017 | 273 | 2.270 |
Why?
|
| Internship and Residency | 5 | 2022 | 578 | 1.930 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2015 | 64 | 1.260 |
Why?
|
| Pancreatectomy | 5 | 2016 | 83 | 1.140 |
Why?
|
| Education, Medical, Graduate | 3 | 2022 | 232 | 0.920 |
Why?
|
| Social Media | 1 | 2021 | 95 | 0.770 |
Why?
|
| Mastectomy | 1 | 2019 | 51 | 0.730 |
Why?
|
| General Surgery | 1 | 2020 | 118 | 0.730 |
Why?
|
| Pancreatitis | 2 | 2009 | 81 | 0.720 |
Why?
|
| Databases, Factual | 2 | 2019 | 721 | 0.710 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 102 | 0.690 |
Why?
|
| Students, Medical | 1 | 2020 | 224 | 0.690 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.620 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 11 | 0.610 |
Why?
|
| Hemangioma | 1 | 2016 | 24 | 0.610 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 18 | 0.590 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 38 | 0.590 |
Why?
|
| Genetic Testing | 1 | 2015 | 112 | 0.560 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 984 | 0.550 |
Why?
|
| Postoperative Complications | 2 | 2019 | 882 | 0.540 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 255 | 0.540 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 123 | 0.520 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2015 | 24 | 0.510 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 166 | 0.510 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 235 | 0.500 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2012 | 2 | 0.490 |
Why?
|
| Retrospective Studies | 11 | 2019 | 4384 | 0.490 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 16 | 0.480 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 26 | 0.480 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2012 | 2 | 0.480 |
Why?
|
| Stomach | 1 | 2010 | 56 | 0.400 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 35 | 0.400 |
Why?
|
| Humans | 25 | 2022 | 48426 | 0.390 |
Why?
|
| Suture Techniques | 1 | 2010 | 71 | 0.390 |
Why?
|
| Pancreas | 1 | 2010 | 139 | 0.390 |
Why?
|
| Hospital Units | 1 | 2008 | 9 | 0.370 |
Why?
|
| Gallstones | 1 | 2008 | 18 | 0.370 |
Why?
|
| Hospital Costs | 1 | 2008 | 96 | 0.340 |
Why?
|
| Risk Factors | 5 | 2019 | 4182 | 0.340 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 1925 | 0.330 |
Why?
|
| Middle Aged | 12 | 2019 | 13427 | 0.320 |
Why?
|
| Patient Admission | 1 | 2008 | 162 | 0.320 |
Why?
|
| Female | 16 | 2022 | 26167 | 0.300 |
Why?
|
| Clinical Competence | 2 | 2020 | 533 | 0.290 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 54 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 76 | 0.270 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 4204 | 0.250 |
Why?
|
| Preoperative Care | 3 | 2019 | 141 | 0.240 |
Why?
|
| Male | 15 | 2022 | 23088 | 0.240 |
Why?
|
| Prognosis | 4 | 2019 | 1244 | 0.230 |
Why?
|
| Aged | 10 | 2017 | 10783 | 0.220 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3804 | 0.220 |
Why?
|
| Burnout, Professional | 1 | 2022 | 76 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 235 | 0.220 |
Why?
|
| Canada | 1 | 2020 | 104 | 0.210 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 184 | 0.200 |
Why?
|
| Inservice Training | 1 | 2020 | 76 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 854 | 0.200 |
Why?
|
| Surgical Oncology | 1 | 2019 | 4 | 0.200 |
Why?
|
| Young Adult | 3 | 2016 | 3600 | 0.190 |
Why?
|
| Certification | 1 | 2019 | 36 | 0.190 |
Why?
|
| Adult | 8 | 2022 | 13163 | 0.190 |
Why?
|
| Learning | 1 | 2020 | 125 | 0.190 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 28 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 104 | 0.180 |
Why?
|
| Hepatectomy | 1 | 2019 | 43 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 2022 | 0.180 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 12 | 0.180 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 11 | 0.180 |
Why?
|
| Mutation | 4 | 2015 | 2224 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 354 | 0.170 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.170 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 4 | 0.160 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 8 | 0.160 |
Why?
|
| Curriculum | 1 | 2020 | 474 | 0.160 |
Why?
|
| Methylene Blue | 1 | 2016 | 22 | 0.160 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 34 | 0.160 |
Why?
|
| Coloring Agents | 1 | 2016 | 51 | 0.160 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 33 | 0.150 |
Why?
|
| United States | 4 | 2022 | 6082 | 0.150 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 11 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2019 | 320 | 0.140 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 19 | 0.140 |
Why?
|
| ras Proteins | 1 | 2015 | 77 | 0.140 |
Why?
|
| Time Factors | 3 | 2019 | 3189 | 0.140 |
Why?
|
| Diet | 1 | 2019 | 595 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 190 | 0.130 |
Why?
|
| Nomograms | 1 | 2013 | 15 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2013 | 3 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 174 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2010 | 2043 | 0.130 |
Why?
|
| Melanoma | 1 | 2016 | 282 | 0.130 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 31 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 301 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 575 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 53 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2012 | 257 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 202 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 366 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 426 | 0.110 |
Why?
|
| Adolescent | 2 | 2012 | 5292 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2012 | 151 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 632 | 0.100 |
Why?
|
| Pancreatic Fistula | 1 | 2010 | 5 | 0.100 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 6 | 0.100 |
Why?
|
| Survival Rate | 1 | 2012 | 664 | 0.100 |
Why?
|
| Neoplasms | 1 | 2019 | 986 | 0.100 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 71 | 0.100 |
Why?
|
| Carrier State | 1 | 2009 | 18 | 0.100 |
Why?
|
| Siblings | 1 | 2009 | 38 | 0.100 |
Why?
|
| Logistic Models | 2 | 2013 | 1168 | 0.090 |
Why?
|
| Pedigree | 1 | 2009 | 167 | 0.090 |
Why?
|
| Cholangiography | 1 | 2008 | 34 | 0.090 |
Why?
|
| Medicare | 1 | 2012 | 434 | 0.090 |
Why?
|
| Cholecystectomy | 1 | 2008 | 34 | 0.090 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 35 | 0.090 |
Why?
|
| Tobacco | 1 | 2009 | 86 | 0.090 |
Why?
|
| Family | 1 | 2009 | 191 | 0.080 |
Why?
|
| Linear Models | 1 | 2008 | 409 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 229 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 264 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2013 | 1573 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1261 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 312 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2008 | 347 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1809 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 1057 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 50 | 0.060 |
Why?
|
| New England | 1 | 2022 | 241 | 0.060 |
Why?
|
| Personnel Selection | 1 | 2022 | 41 | 0.060 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 38 | 0.050 |
Why?
|
| Students | 1 | 2022 | 191 | 0.050 |
Why?
|
| Mammography | 1 | 2021 | 229 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 67 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 29 | 0.040 |
Why?
|
| Mice | 1 | 2010 | 9151 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 59 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 1110 | 0.040 |
Why?
|
| Chromogranins | 1 | 2015 | 11 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 43 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2236 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 854 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 175 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 246 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 190 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 203 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 401 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 371 | 0.030 |
Why?
|
| SEER Program | 1 | 2012 | 68 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 768 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 706 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 943 | 0.030 |
Why?
|
| Health Services | 1 | 2012 | 84 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2012 | 208 | 0.030 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 10 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1311 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 79 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 165 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 111 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1122 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 2473 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 18037 | 0.010 |
Why?
|